Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Income (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Net Income data on record, last reported at -$5.7 million in Q4 2025.

  • For Q4 2025, Net Income rose 75.91% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached -$23.4 million, up 73.43%, while the annual FY2025 figure was -$23.4 million, 73.43% up from the prior year.
  • Net Income reached -$5.7 million in Q4 2025 per MIRM's latest filing, down from $2.9 million in the prior quarter.
  • Across five years, Net Income topped out at $57.3 million in Q4 2021 and bottomed at -$74.0 million in Q2 2023.
  • Average Net Income over 5 years is -$24.7 million, with a median of -$26.1 million recorded in 2022.
  • Peak YoY movement for Net Income: skyrocketed 253.97% in 2021, then crashed 175.01% in 2023.
  • A 5-year view of Net Income shows it stood at $57.3 million in 2021, then tumbled by 163.6% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then surged by 33.28% to -$23.8 million in 2024, then soared by 75.91% to -$5.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$5.7 million in Q4 2025, $2.9 million in Q3 2025, and -$5.9 million in Q2 2025.